CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms
Author Information
Author(s): Han Seong-Su, Peng Liangping, Chung Seung-Tae, DuBois Wendy, Maeng Sung-Ho, Shaffer Arthur L, Sporn Michael B, Janz Siegfried
Primary Institution: National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA
Hypothesis
CDDO-imidazolide (CDDO-Im) can inhibit the growth and survival of Myc-induced B cell and plasma cell neoplasms.
Conclusion
CDDO-Im effectively causes growth arrest and apoptosis in neoplastic mouse B cells and plasma cells.
Supporting Evidence
- CDDO-Im caused growth arrest and apoptosis in both iMycEμ-1 and iMycEμ-2 cells.
- Treatment with CDDO-Im resulted in a significant reduction in cell proliferation.
- CDDO-Im treatment led to the up-regulation of 30 genes involved in apoptosis and stress responses.
Takeaway
A new drug called CDDO-Im can stop certain cancer cells from growing and even make them die.
Methodology
The study used cell lines derived from Myc-induced neoplasms to evaluate the effects of CDDO-Im on cell growth and apoptosis through various assays.
Limitations
The small sample size in the in vivo study limits the statistical significance of the findings.
Participant Demographics
The study involved transgenic mice (iMycEμ) that develop B cell and plasma cell tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website